Core Viewpoint - The company, Weiyuan Co., expects a significant net loss for the year 2025, projecting a net profit attributable to shareholders of between -950 million yuan and -1.05 billion yuan, indicating a downturn compared to the previous year [1] Group 1: Financial Performance - The anticipated loss is primarily due to a substantial decline in average prices of key products such as phenol, acetone, isopropanol, bisphenol A, and polycarbonate in 2025 compared to 2024 [1] - The company's gross profit margin is expected to decrease as a result of the lower product prices [1] Group 2: Operational Challenges - Increased costs associated with equipment maintenance and the trial production of new projects are contributing factors to the projected losses [1] - The intensifying industry competition has led to some product prices remaining at relatively low levels, adversely affecting the profitability of certain facilities, such as those producing electrolyte solvents [1] Group 3: Asset Management - The company has adopted a cautious approach by making provisions for impairment on relevant long-term assets and inventory, which significantly impacts the current period's performance [1]

维远股份1月16日公告，经财务部门初步测算，预计2025年年度实现归属于上市公司股东的净利润为 为-95,000 万元到-105,000 万元，其中部分长期资产、存货等计提减值准备影响归属于上市公司股东的 净利润约-63,000万元，与上年同期相比，将出现亏损。 ...

Core Viewpoint - The company expects a net profit loss attributable to shareholders of 950 million to 1.05 billion yuan for the year 2025, primarily due to significant declines in average prices of key products [1] Group 1: Financial Forecast - The projected net profit loss for 2025 is between 950 million and 1.05 billion yuan [1] - The decline in profitability is attributed to the cyclical nature of the industry [1] Group 2: Product Price Impact - Major products such as phenol, acetone, isopropanol, bisphenol A, and polycarbonate are expected to see substantial average price decreases in 2025 compared to 2024 [1] - The decrease in product prices is anticipated to lead to a reduction in gross profit margins for the company [1]

Group 1 - The core point of the article is that Weiyuan Co., Ltd. (维远股份) has announced that its performance for 2025 is expected to be below expectations due to factors such as declining product prices, leading to a projected net loss for the year [1] - Weiyuan Co., Ltd. was listed on the Shanghai Stock Exchange on September 15, 2021, with an initial public offering of 138 million shares at a price of 29.56 yuan per share, and the stock is currently trading below its initial offering price [1] - The total amount raised from the initial public offering was 4.065 billion yuan, with a net amount of 3.88 billion yuan after deducting issuance costs, which was 2 billion yuan more than originally planned [1] Group 2 - In 2024, Weiyuan Co., Ltd. achieved an operating revenue of 9.522 billion yuan, representing a year-on-year increase of 35.06%, while the net profit attributable to shareholders decreased by 42.62% to 56.59 million yuan [2] - The company's net profit after deducting non-recurring gains and losses was 45.31 million yuan, down 36.85% year-on-year, while the net cash flow from operating activities increased by 49.52% to 918 million yuan [2]

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

利华益维远化学股份有限公司 公司严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，在规定时限内尽 快披露2025年度业绩预告。具体准确的财务数据以公司正式披露的经审计后的2025年年度报告为准。 本次业绩预告提示性公告是公司财务部门基于公司年度经营情况和自身专业判断进行的初步测算，未经 注册会计师审计。敬请广大投资者理性投资，注意投资风险。 证券代码：600955 证券简称：维远股份 公告编号：2026-002 关于2025年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 2025年，利华益维远化学股份有限公司（以下简称"公司"）面对严峻的市场形势，积极应对挑战，坚持 绿色低碳发展方向和实体产业不动摇，发挥产业链优势，实施"深耕细管、降本增效"主题管理，不断降 低生产成本。受产品价格下降等因素影响，公司业绩不及预期。 经公司财务部门初步测算，预计2025年度归属于上市公司股东的净利润为负值，公司2025年度经营业绩 将出现亏损。 特此公告。 利华益维远化学股份有限公司董事会 ...

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]

本次业绩预告提示性公告是公司财务部门基于公司年度经营情况和自 身专业判断进行的初步测算，未经注册会计师审计。敬请广大投资者理性 投资，注意投资风险。 证券代码：600955 证券简称：维远股份 公告编号：2026-002 利华益维远化学股份有限公司 关于 2025 年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年，利华益维远化学股份有限公司（以下简称"公司"）面对严 峻的市场形势，积极应对挑战，坚持绿色低碳发展方向和实体产业不动摇， 发挥产业链优势，实施"深耕细管、降本增效"主题管理，不断降低生产 成本。受产品价格下降等因素影响，公司业绩不及预期。 经公司财务部门初步测算，预计 2025 年度归属于上市公司股东的净利 润为负值，公司 2025 年度经营业绩将出现亏损。 公司严格遵循《上海证券交易所股票上市规则》等相关规定，加快推 进财务核算工作，在规定时限内尽快披露 2025 年度业绩预告。具体准确的 财务数据以公司正式披露的经审计后的 2025 年年度报告为准。 特此公告。 利华益 ...

北京商报讯（记者 马换换 李佳雪）1月11日晚间，维远股份（600955）披露公告称，经公司财务部门初 步测算，预计2025年度归属净利润为负值，公司2025年度经营业绩将出现亏损。 维远股份表示，受产品价格下降等因素影响，公司业绩不及预期。 ...

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]